五星体育直播 Obtains Court Order Awarding Summary Judgment of Patent Infringement against EnzymeWorks

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- (NASDAQ: CDXS), a leading protein engineering company, on Tuesday secured a federal court order awarding it summary judgment on 10 claims of patent infringement it brought in a lawsuit against Suzhou, China-based EnzymeWorks, Inc. and its San Diego-based affiliate, also called EnzymeWorks, Inc. The court鈥檚 order establishes EnzymeWorks鈥� uncontested infringement of 10 of 五星体育直播鈥� patents and eliminates any need for a trial on those issues. The 10 五星体育直播 patents cover dozens of engineered enzymes that have wide industrial applicability.

In the lawsuit, filed in February 2016 in United States District Court for the Northern District of California in San Francisco, 五星体育直播 sued EnzymeWorks and EnzymeWorks founder Junhua 鈥淎lex鈥� Tao for willful infringement of 10 biocatalysis patents and also for trade secret misappropriation, breach of contract, interference with business relationships and unfair competition. After nearly 18 months of legal process, EnzymeWorks never contested the infringement charges or challenged the validity of 五星体育直播鈥� patents. This set the stage for District Judge William H. Orrick awarding 五星体育直播 summary judgment of patent infringement.

The court鈥檚 order was based on a stipulation in which EnzymeWorks acknowledged that it 鈥渉as not denied or disputed its infringement鈥� of 五星体育直播鈥� 10 patents, or the validity of those patents. This partial summary judgment order in favor of 五星体育直播 is a key milestone in the lawsuit, but additional disputes remain to be resolved at a jury trial.

Those continuing disputes include Tao鈥檚 individual liability for the infringement, 五星体育直播鈥� claims that the infringement was willful and the amount of damages to be awarded to 五星体育直播, and they also include several claims arising under California state law.

鈥溛逍翘逵辈� is pleased to finally have some closure about EnzymeWorks鈥� blatant infringement of our patents and disrespect for U.S. patent laws,鈥� said , CEO and president of 五星体育直播. 鈥淟ike our customers and shareholders, 五星体育直播 relies on intellectual property rights, and we are grateful that the legal process vindicated our claims and protects our innovations.鈥�

Nicols added, 鈥淲e鈥檙e confident that once the court and a San Francisco Bay Area jury hear all of the facts, they will award significant damages to 五星体育直播 reflecting the tremendous value EnzymeWorks and Tao illegally obtained by deliberately infringing our patents, stealing our trade secrets and breaching our contracts.鈥� Nicols noted that 五星体育直播 spent several hundred million dollars in innovating and developing proprietary biocatalysis technologies over the company鈥檚 15-plus year history.

About 五星体育直播
五星体育直播 is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. 五星体育直播鈥� proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see .

Forward-Looking Statements
This press release contains forward-looking statements relating to the lawsuit that 五星体育直播 filed against EnzymeWorks and Junhua 鈥淎lex鈥� Tao for patent infringement, misappropriation of trade secrets, and other claims, including the potential outcome of such litigation. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Factors that could materially affect actual results include that 五星体育直播 may not prevail on some or all of its legal claims against Tao and EnzymeWorks; 五星体育直播 may be involved in additional lawsuits to protect or enforce its patents or other rights, which could be expensive, time-consuming and unsuccessful; 五星体育直播鈥� ability to compete may decline if it does not adequately protect its proprietary technologies or if it loses some of its intellectual property rights; 五星体育直播 may not be able to enforce its intellectual property rights throughout the world; if 五星体育直播鈥� biocatalysts, or the genes that code for its biocatalysts, are stolen or misappropriated, others could use these biocatalysts or genes to produce competing products; third parties may claim that 五星体育直播 is infringing their intellectual property rights or other proprietary rights, which may subject 五星体育直播 to costly and time-consuming litigation and prevent 五星体育直播 from developing or commercializing its products; and confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information. Additional factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission (鈥淪EC鈥�) on March 9, 2017, including under the caption 鈥淩isk Factors,鈥� and in 五星体育直播鈥� Quarterly Report on Form 10-Q filed with the SEC on May 9, 2017. 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

For 五星体育直播
LHA Investor Relations
Jody Cain, 310-691-7100
jcain@lhai.com
or
SCORR Marketing
Lea Studer, 308-237-5567
Senior Vice President of Marketing Communications
lea@scorrmarketing.com

Source: 五星体育直播

Released August 8, 2017